Multiple endocrine neoplasia type 1 future or investigational therapies: Difference between revisions
No edit summary |
|||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping. | Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors ([[tropomyosin]] receptor kinase inhibitors), mTOR inhibitors, [[thienopyrimidine]] analogs and molecular [[phenotyping]]. | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
* Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.<ref name="pmidhttp://dx.doi.org/10.1210/jc.2012-1230">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1210/jc.2012-1230 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref> | * Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.<ref name="pmidhttp://dx.doi.org/10.1210/jc.2012-1230">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1210/jc.2012-1230 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref> | ||
Line 13: | Line 13: | ||
* [[Thienopyrimidine]] analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1. | * [[Thienopyrimidine]] analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1. | ||
* Molecular [[phenotyping]] of [[tumor]]s have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage. | * Molecular [[phenotyping]] of [[tumor]]s have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage. | ||
==Reference== | ==Reference== | ||
{{Reflist}} | {{Reflist}} | ||
[[Category:Hereditary cancers]] | [[Category:Hereditary cancers]] |
Revision as of 16:45, 11 September 2015
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 future or investigational therapies On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 future or investigational therapies |
FDA on Multiple endocrine neoplasia type 1 future or investigational therapies |
CDC on Multiple endocrine neoplasia type 1 future or investigational therapies |
Multiple endocrine neoplasia type 1 future or investigational therapies in the news |
Blogs on Multiple endocrine neoplasia type 1 future or investigational therapies |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping.
Future or Investigational Therapies
- Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.[1]
- National and international collaborations are encouraged to recruit more patients with multiple endocrine neoplasia type 1 for clinical trials.
- Use of TRK inhibitors (tropomyosin receptor kinase inhibitors) for medullary thyroid cancer and pancreatic neuroendocrine tumors have been investigated under multicenter clinical trials.
- mTOR inhibitors for pancreatic neuroendocrine tumors are other subjects undergoing investigation.
- Role of surgery for non functioning pancreatic neuroendocrine tumors is also under investigation.
- The interaction between menin and mixed lineage leukemia protein 1(MLL1) also known as a histone H3 lysine 4 methyltransferase has been targeted to find cure for multiple endocrine neoplasia type 1
- Thienopyrimidine analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1.
- Molecular phenotyping of tumors have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage.
Reference
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID http://dx.doi.org/10.1210/jc.2012-1230 Check
|pmid=
value (help).